Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023

Rhea-AI Summary

Catalyst Pharmaceuticals (CPRX) is set to release its Q1 2023 financial results after market close on May 10, 2023. A conference call and webcast discussing the results will take place on May 11, 2023, at 8:30 AM ET. The company specializes in developing innovative medicines for rare diseases, with its key product being FIRDAPSE for Lambert-Eaton myasthenic syndrome. Additionally, Catalyst recently acquired U.S. commercial rights to FYCOMPA, an epilepsy treatment approved for patients aged four and older. The company highlights its commitment to patient care and innovative solutions in the biopharmaceutical sector. Investors can access the webcast via their official website, where a replay will be available for 30 days.

Positive

• Catalyst's flagship product, FIRDAPSE, is approved for adult and pediatric patients with LEMS.
• Acquisition of U.S. rights to FYCOMPA enhances Catalyst's product portfolio in epilepsy treatment.

Negative

• None.

The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET

CORAL GABLES, Fla., April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its first-quarter 2023 financial results after market close on Wednesday, May 10, 2023.

Catalyst’s management team will host a conference call and webcast the following morning, Thursday, May 11, 2023, at 8:30 AM ET, to discuss the Company’s financial results and provide a corporate update.

Conference Call & Webcast Details

Date/Time:	May 11, 2023, at 8:30 AM ET
US/Canada Dial-in Number:	(877) 407-8912
International Dial-in Number:	(201) 689-8059

A webcast and accompanying materials will be accessible under the Investors section on the Company’s website at www.catalystpharma.com. A replay of the webcast will be available on the Catalyst website for 30 days following the date of the event.

About Catalyst Pharmaceuticals
With exceptional patient focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare neurological and epileptic diseases. Catalyst’s flagship U.S. commercial product is FIRDAPSE^® (amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”) for adults and for children ages six to seventeen. In January 2023, Catalyst acquired the U.S. commercial rights to FYCOMPA^® (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older. Further, Canada’s national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

For more information about Catalyst Pharmaceuticals, Inc., visit the Company’s website at: www.catalystpharma.com. For the Full Prescribing and Safety Information for FIRDAPSE^®, please visit www.firdapse.com. For the Full Prescribing Information for FYCOMPA^®, please visit www.fycompa.com. See below for the Boxed Warning for FYCOMPA^®:

IMPORTANT SAFETY INFORMATION FOR FYCOMPA^®

WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA Closely monitor patients particularly during the titration period and at higher doses FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2022 and its other filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

FAQ

When will Catalyst Pharmaceuticals release its Q1 2023 financial results?

Catalyst Pharmaceuticals will release its Q1 2023 financial results after market close on May 10, 2023.

When is the Catalyst Pharmaceuticals conference call for Q1 2023 results?

The conference call will be held on May 11, 2023, at 8:30 AM ET.

What products does Catalyst Pharmaceuticals focus on?

Catalyst Pharmaceuticals develops treatments for rare neurological and epileptic diseases, notably FIRDAPSE and FYCOMPA.

What are the indications for FIRDAPSE?

FIRDAPSE is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS).

What is FYCOMPA used for?

FYCOMPA is approved for treating partial-onset seizures in people with epilepsy aged four and older.